We describe an allogeneic bone marrow (BM) recipient who developed aggressive, metastasizing squamous cell cancer (SCC) of the skin, and discuss possible risk factors in the development of this secondary solid tumor. The patient had been treated with cyclosporine (CsA), methyl-prednisolone and thalidomide for 3 years because of extensive de novo chronic cutaneous GVHD occurring 1 year after BMT. Ten years after BMT a locally invasive and metastasizing SCC occurred on the patient's neck, and diagnosis was confirmed by H&E histopathology and cytokeratin-immunohistochemistry. Analysis of genomic DNA did not reveal p53 mutations nor were HPV sequences detectable. Risk factors included conditioning for BMT with total body irradiation (TBI) and cyclophosphamide (Cy), immunosuppressive treatment for GVHD, and extensive exposure to UV radiation before and after BMT. Despite surgery and adjuvant chemotherapy with 5-fluorouracil (5-FU) the patient died 1 year after the diagnosis of SCC. Keywords: secondary malignancy; squamous cell carcinoma; GVHD; immunosuppression With numbers of BM transplants from related and unrelated donors increasing recently the frequency of secondary neoplasms which impair long-term outcome and survival of the BM recipients has also been increasing. The risk of developing secondary cancer after allogeneic BMT has been reported to be increased 6.69-to 11-fold over that of an age-matched population.
With numbers of BM transplants from related and unrelated donors increasing recently the frequency of secondary neoplasms which impair long-term outcome and survival of the BM recipients has also been increasing. The risk of developing secondary cancer after allogeneic BMT has been reported to be increased 6.69-to 11-fold over that of an age-matched population. 1, 2 Whereas lymphoproliferative cancers, myelodysplastic syndrome, acute leukemia and non-Hodgkin's lymphoma predominate in the first years after BMT, solid cancers including neoplasms of the central nervous system, bone, inner organs, skin and mucosal sur- faces occur progressively 10-15 years thereafter. [1] [2] [3] The largest cohort study on nearly 20 000 allogeneic BM recipients showed the cumulative incidence for secondary solid tumors to be 6.7%.
Case report
SCC was diagnosed in a previously healthy 26-year-old Caucasian male patient in January 1985 who subsequently received 8 units of packed red blood cells and 4 units of platelets. Five months later, after conditioning with 200 mg Cy/kg body weight (b.w.) over 4 days and TBI of 3 Gy, he received 2.7 ϫ 10 8 nucleated cells (NC)/kg b.w. from his HLA class I and II identical brother. Methotrexate (MTX) according to the Seattle protocol was used as GVHD prophylaxis. Neutrophil counts of more than 0.5 ϫ 10 9 /l and 1 ϫ 10 9 /l were reached on days ϩ35 and ϩ53, respectively, after BMT. Unsupported platelets Ͼ20 ϫ 10 9 /l, hematocrit Ͼ30% and reticulocytes Ͼ20 000/ml without the need for further transfusion were reached on days ϩ24 and ϩ12, respectively. Donor cell engraftment was documented by the presence of donor ABO blood group. Because of poor marrow function MTX was stopped on day ϩ39. The patient showed no signs of acute GVHD and was discharged on day ϩ49 post BMT.
One year after BMT, he developed de novo onset chronic cutaneous GVHD with lichenoid lesions on the lips and oral mucosa. We initiated systemic immunosuppression with 1.5 mg prednisolone/kg b.w./day and CsA 5 mg/kg b.w./day. Despite systemic immunosuppression, the cutaneous lesions progressed into chronic scleroderma-like GVHD involving the neck, upper trunk, and upper and lower extremities with thickening of the dermis and contractures of the joints, within 10 months. In addition to prednisolone 25 mg alternate day (a.d.) and CsA 2.5 mg/kg b.w. daily thalidomide was started (4) at 100 mg/day, and the daily dose was increased to 300 mg within 4 weeks. Three months after initiation of thalidomide treatment the scleroderma-like lesions appeared softer, and joint contractures were less disabling. No further progression of chronic GVHD was noted.
While he was on combined immunosuppressive therapy painless plaque with ulceration on his right shoulder. This lesion was interpreted by the patient as a trophic ulcer similar to those he had developed on his legs several years before. Upon referral to our clinic a flat, non-painful ulcer, 10 ϫ 14 cm in size, with markedly elevated borders ( Figure  3 ) was seen within an area of chronic cutaneous GVHD (epidermal atrophy, dyspigmentation and fibrosis/sclerosis), highly suggestive of skin cancer. Histologic examination and immunohistochemistry with the pan-cytokeratin marker AE1/AE3 confirmed the diagnosis of SCC with malignant epithelial cells containing multiple mitoses (Figure 4 ). One biopsy specimen was studied for the presence of human papilloma virus (HPV). Polymerase chain reaction (PCR) was conducted on the purified DNA using one set of consensus primers from the E1 open reading frame of HPV. 5 However, no HPV fragments could be generated from the patient's sample. In addition, no mutation in the p53 gene was detected by single-strand conformation polymorphism (SSCP) analysis. 6 Four weeks after surgery local tumor cell infiltration of the M. trapezius and the clavicula had developed. The clavicula and parts of the M. trapezius were removed before reconstruction of the defect with a flap patch derived from the M. latissimus dorsi. By then, cervical and axillary lymph nodes were infiltrated with a rapidly growing tumor. Local irradiation and chemotherapy with 5-fluorouracil, 450 mg/m 2 , was initiated. The patient died 1 year after the diagnosis of SCC of the skin from widespread metastatic disease.
Discussion
Skin and mucosal neoplasms account for approximately one-third of all secondary tumors after BMT, with SCC representing the majority of cases at about 50%. 3 Similarly, a significant incidence of skin cancer has been documented in solid organ transplant recipients with a 20-fold increased risk for developing SCC in kidney and heart transplant recipients. 7 Skin tumors behave more aggressively in these patients than in immunocompetent individuals and have a higher risk of metastasis. 7 It was not until this year that chronic GVHD without treatment was shown to be linked with a higher risk of SCC of the skin and buccal cavity. 3 Irradiation and immunosuppressive drugs are used for conditioning and for prophylaxis/treatment of GVHD. The risk of cancer developing in patients who underwent irradiation before BMT is up to 18.4 times higher than the risk for those who did not undergo irradiation.
3 Consistent with this observation, an increased incidence of cancer was previously observed in dogs given TBI before transplant (no relationship with increasing dosage was indicated) compared to dogs not receiving TBI.
8 Azathioprine (AZA) and CsA have been reported to be associated with an increased risk for secondary neoplasms in solid organ transplant recipients 7 and, also, AZA appears to promote/facilitate secondary neoplasms when used as treatment for chronic GVHD. 9 In contrast to AZA, CsA is not mutagenic but rather impairs functional T cell-mediated tumor surveillance. Thus, immunosuppression with CsA for an extended period may have contributed significantly to the development of SCC in our patient.
UV-exposure pre or post BMT may induce loss of repair mechanisms causing transformation of various cell types. Combined effects of UV exposure and immunosuppressive drugs cannot be excluded. Kelly et al 10 have documented the tumor-promoting effect of chemical immunosuppressants on UV light induced skin carcinogenesis in hairless albino mice. Therefore, it seems likely that TBI (3 Gy), Cy (200 mg/kg body weight), chronic scleroderma-like GVHD and our patient's history of extensive UV exposure pre and post transplant due to his outdoor activities have caused the cutaneous SCC.
In addition, infectious agents leading to host cell transformation may be considered. Oncogenic HPV types have been detected in SCC in up to 80% of renal transplant recipients, depending on the sensitivity of the molecular technique. 11 Failure to detect HPV DNA in the tumor sample of our patient by a one-step PCR does not exclude HPV infection having contributed to the tumor development as a 'hit and run' mechanism with loss of the oncogenic virus sequences in the fully developed tumor as has been described in an animal cocarcinogenesis model. 12 The excess risk of transplanted male patients developing SCC of the skin and the buccal cavity is unexplained. 3 The male H-Y antigen is a minor histocompatibility antigen which is presented to immunocompetent female donor T lymphocytes in association with particular host class-I alloantigen polymorphisms. Therefore, the somewhat increased incidence of GVHD following transplantation of female-derived BM into male recipients is an additional risk factor for the development of SCC over male sex per se.
Based on the knowledge that the risk of developing secondary cutaneous neoplasms increases after allogeneic BMT, patients require regular life-long dermatologic follow-up examinations but should also be alerted to carry out self-observation.
